The failure of Medtronic's Symplicity 3 trial doesn't mean the end of renal denervation in treated resistant hypertension, especially in Europe, but future studies face a high bar set by the Medtronic trial's sham control arm.
Kona Medical announces the launch of a clinical trial for its non-invasive Surround Sound renal denervation device for treating hypertension.
Kona Medical said this week that it's launched a clinical trial of the non-invasive renal denervation device for treating hypertension it calls Surround Sound.
Researchers develop a "surveillance system" to monitor patients' electronic health records for signs of undiagnosed hypertension.
MASSDEVICE ON CALL — A computer algorithm may be able to help physicians monitor patients for signs of hypertension, a disease known as "the silent killer."
Researchers at Northwestern Medicine developed a trio of algorithms to review patients' electronic health records and alert healthcare providers that a patient may have or may be developing hypertension.
Twitter-savvy physicians and researchers mull over the latest clinical results for Medtronic's renal denervation technology, calling for more common sense and less hype in treating hypertension.
Doctors and researchers at this year's EuroPCR conference look for answers in Medtronic's landmark SYMPLICITY HTN-3 clinical trial, which failed to find that renal denervation works against hypertension.
Amid the hand-wringing and back-pedaling surrounding renal denervation, some physicians are still looking for ways to use the technology to treat patients with hypertension.
St. Jude Medical says that its next-gen EnligHTN renal denervation system appears safe and effective in treating hypertension, but docs at this year's EuroPCR conference are calling for more robust clinical trials.
The marketing push for hypertension-treating renal denervation technology, clinical darling turned black sheep, has some doctors raising eyebrows at the EuroPCR conference in Paris this week.
Attendees at this year's EuroPCR conference in Paris cast a wary eye on medical device makers' efforts to promote renal denervation in treatment of hypertension, taking to Twitter to note and sometimes chide companies for putting "marketing before science."